A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes
- 1 August 2009
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (8), 2792-2798
- https://doi.org/10.1210/jc.2008-2157
Abstract
Context: Thiazolidenediones (TZDs) are selective ligands of peroxisome-proliferator-activated receptor-γ and have been shown to reduce bone mineral density. Recent results from several randomized controlled trials find an increased risk of fracture with TZDs compared with other oral antidiabetic agents. Objective: The aim of the study was to determine the association between TZD use and fracture risk among older adults with diabetes. Design: We conducted a cohort study. Participants: Medicare beneficiaries with at least one diagnosis of diabetes initiating monotherapy for an oral hypoglycemic agent participated in the study. Main Outcome: We measured the incidence of fracture within the cohort. Results: Among the 20,964 patients with diabetes eligible for this study, 686 (3.3%) experienced a fracture during the median follow-up of approximately 10 months. Although not statistically significant, patients using only a TZD were more likely to experience a fracture than those using metformin (adjusted relative risk, 1.31; 95% confidence interval, 0.98–1.77; P = 0.071) or a sulfonylurea (adjusted relative risk, 1.21; 95% confidence interval, 0.94–1.55; P = 0.12). Each individual TZD was associated with an increased risk, with confidence intervals overlapping unity, compared with both metformin and sulfonylureas. The adjusted risk of any fracture associated with TZD use compared with metformin was elevated for non-insulin-using patients, women and men. If TZD use is associated with fractures, the number needed for one excess fracture when comparing TZD users to sulfonylurea users was 200, and the number was 111 when comparing TZDs with metformin. Conclusions: As has been found with other analyses, our data suggest that TZDs may be associated with an increased risk of fractures compared with oral sulfonylureas and metformin.Keywords
This publication has 16 references indexed in Scilit:
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisCMAJ : Canadian Medical Association Journal, 2009
- Identification and Validation of Vertebral Compression Fractures Using Administrative Claims DataMedical Care, 2009
- Rosiglitazone-Associated Fractures in Type 2 DiabetesDiabetes Care, 2008
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsJournal of Clinical Endocrinology & Metabolism, 2006
- Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeuticsPharmacoepidemiology and Drug Safety, 2006
- A review of uses of health care utilization databases for epidemiologic research on therapeuticsJournal of Clinical Epidemiology, 2005
- Activation of Peroxisome Proliferator-activated Receptor-γ Pathway Inhibits Osteoclast DifferentiationJournal of Biological Chemistry, 2000
- Identification of fractures from computerized medicare filesJournal of Clinical Epidemiology, 1992
- A Strengthening Programme for Weak AssociationsInternational Journal of Epidemiology, 1988